AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32183783 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Girls Empowerment Program (AGEP)
Number of subjects: 4661
Study 32183783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4661
Study 33434704 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND diet with mild caloric restriction
Number of subjects: 604
Study 33434704 — intervention group
Group type: COMPARATOR
Intervention: Usual diet with mild caloric restriction
Number of subjects: 604
Study 36350478 — intervention group
Group type: EXPERIMENTAL
Intervention: HRVB
Number of subjects: 64
Study 36350478 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 64
Study 33606577 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 2729
Study 33606577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2729
Study 32460618 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy using low energy, nonionizing light primarily in the visible or near-infrared spectrum.
Number of subjects: 0
Study 32460618 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 35228279 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofenix platform for home‐based rehabilitation of the upper limb
Number of subjects: 30
Study 32205155 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 °C
Number of subjects: 0
Study 32205155 — intervention group
Group type: COMPARATOR
Intervention: Normothermia and early treatment of fever (≥37.8 °C)
Number of subjects: 0
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and stress testing parameters
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of prior myocardial infarction
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic dilation of the left ventricle on stress echocardiography
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of ST-segment depression on ETT
Number of subjects: 5146
Study 35177194 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak metabolic equivalents achieved on ETT
Number of subjects: 5146
Study 34304264 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB transitional care programme (comprehensive geriatric assessment-based integrated care plan, face-to-face handover with community nurse, follow-up home visits, home-based cardiac rehabilitation)
Number of subjects: 306
Study 34304264 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 306
Study 35180099 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston Technique (GT) combined with Conventional Physical Therapy (CPT)
Number of subjects: 30
Study 35180099 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 30
Study 36161973 — intervention group
Group type: EXPERIMENTAL
Intervention: iBDecide (n=14)
Number of subjects: 35
Study 35419831 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with S‐1 (CCRT)
Number of subjects: 157
Study 35419831 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 157
Study 32139204 — intervention group
Group type: COMPARATOR
Intervention: IV chlorpheniramine (CPM)
Number of subjects: 75
Study 32139204 — intervention group
Group type: COMPARATOR
Intervention: IV chlorpheniramine (CPM) and IV dexamethasone (CPM/Dex)
Number of subjects: 75
Study 32139204 — intervention group
Group type: EXPERIMENTAL
Intervention: IV chlorpheniramine (CPM), IV dexamethasone (CPM/Dex), and oral prednisolone for 5 days (CPM/Dex/Pred)
Number of subjects: 75
Study 32871535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0
Study 32871535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36065850 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 18
Study 36065850 — intervention group
Group type: COMPARATOR
Intervention: Core Stabilization Training (CT)
Number of subjects: 18
Study 32349359 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation V2 (R&R2) programme
Number of subjects: 142
Study 32349359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 142
Study 33450430 — intervention group
Group type: EXPERIMENTAL
Intervention: Team handball group (THG, n = 41)
Number of subjects: 67
Study 33450430 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 26)
Number of subjects: 67
Study 34018371 — intervention group
Group type: EXPERIMENTAL
Intervention: IC‐ECG guidance combined with conventional anatomical landmark guidance (n=105)
Number of subjects: 210
Study 34018371 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomical landmark guidance (n=105)
Number of subjects: 210
Study 36281627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (333 mg oral dose)
Number of subjects: 15
Study 36281627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 33248918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial BMSC injection (group B)
Number of subjects: 81
Study 33248918 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (group A)
Number of subjects: 81
Study 34982354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported anchors
Number of subjects: 154
Study 33026658 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT‐CARE
Number of subjects: 100
Study 33026658 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 35912647 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT followed by clopidogrel monotherapy
Number of subjects: 5997
Study 35912647 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT with aspirin and clopidogrel
Number of subjects: 5997
Study 34339469 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Number of subjects: 17849
Study 34339469 — intervention group
Group type: EXPERIMENTAL
Intervention: BB
Number of subjects: 17849
Study 32486595 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral CT-based radiomics
Number of subjects: 196
Study 32486595 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-reported LN status
Number of subjects: 196
Study 32486595 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signatures (40 keV-arterial phase, 65 keV-venous phase, IC-VP of tumor, CT-reported LN status)
Number of subjects: 196
Study 32486595 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 196
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical injection group (1 ml of nano-carbon injected at 3 and 9 o'clock in the cervix)
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine injection group (4 ml of methylene blue injected into the uterine body at 2 sites)
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined injection group (1 ml of nano-carbon + 4 ml of methylene blue)
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results for all patients
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-high risk patients
Number of subjects: 73
Study 36456477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological super-staging results
Number of subjects: 73
Study 34237608 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially expressed circRNAs in testes and ovaries, including 541 upregulated and 169 downregulated circRNAs in testes.
Number of subjects: 0
Study 34237608 — intervention group
Group type: EXPERIMENTAL
Intervention: Five DE circRNAs selected for quantitative real-time PCR analysis.
Number of subjects: 0
Study 34237608 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted interactions between circRNAs and miRNAs.
Number of subjects: 0
Study 34237608 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructed ceRNA networks.
Number of subjects: 0
Study 35024154 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative hypotension-avoidance strategy
Number of subjects: 6800
Study 35024154 — intervention group
Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy (Control)
Number of subjects: 6800
Study 32682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (anti-CTLA-4 antibody)
Number of subjects: 0
Study 34366134 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-facilitated discussion groups over 6 months
Number of subjects: 125
Study 34366134 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 34709010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.25 µg/kg/h)
Number of subjects: 0
Study 34709010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.5 µg/kg/h)
Number of subjects: 0
Study 34709010 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 0
Study 34157981 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTICA trial participants
Number of subjects: 323
Study 34157981 — intervention group
Group type: COMPARATOR
Intervention: FIRE database patients
Number of subjects: 323
Study 36429418 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cardiac rehabilitation (CR) with breathing exercises (BE) including inspiratory muscle training (IMT) and breathing calisthenics (BC)
Number of subjects: 40
Study 36429418 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR) alone
Number of subjects: 40
Study 33836311 — intervention group
Group type: COMPARATOR
Intervention: Traditional Advance Directive (AD)
Number of subjects: 126
Study 33836311 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter Advance Directive (AD)
Number of subjects: 126
Study 33836311 — intervention group
Group type: COMPARATOR
Intervention: Traditional AD and Letter AD
Number of subjects: 126
Study 32900389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne rapid maxillary expansion (TB-RME)
Number of subjects: 40
Study 32900389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne rapid maxillary expansion (BB-RME)
Number of subjects: 40
Study 32900389 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TB-RME and BB-RME
Number of subjects: 40
Study 35260255 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser melting (SLM) frameworks
Number of subjects: 29
Study 35260255 — intervention group
Group type: COMPARATOR
Intervention: Traditional frameworks
Number of subjects: 29
Study 36028279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine (25‐day course)
Number of subjects: 2472
Study 36028279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2472
Study 33006501 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-placental IUD insertion
Number of subjects: 1000
Study 33006501 — intervention group
Group type: COMPARATOR
Intervention: Puerperal IUD insertion
Number of subjects: 1000
Study 33411391 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training intervention
Number of subjects: 0
Study 33411391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33039658 — intervention group
Group type: EXPERIMENTAL
Intervention: Enk™
Number of subjects: 160
Study 33039658 — intervention group
Group type: COMPARATOR
Intervention: Manujet™
Number of subjects: 160
Study 35728675 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counselling (GC)
Number of subjects: 420
Study 35728675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study 33608212 — intervention group
Group type: COMPARATOR
Intervention: Checkpoint inhibitor (CPI) immunotherapy alone (n = 19)
Number of subjects: 35
Study 33608212 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI immunotherapy in combination with 4 cycles doublet carboplatin/pemetrexed chemotherapy and 3 to 5 fractions SBRT (n = 16)
Number of subjects: 35
Study 33608212 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent course of SBRT based on response (n = 15)
Number of subjects: 35
Study 33998099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg/day)
Number of subjects: 1592
Study 33998099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1592
Study 33106028 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (single injection, with or without ultrasound guidance)
Number of subjects: 36
Study 33106028 — intervention group
Group type: EXPERIMENTAL
Intervention: Second corticosteroid injection
Number of subjects: 36
Study 33106028 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 36
Study 33106028 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (across all groups)
Number of subjects: 36
Study 32379134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 267
Study 32379134 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 267
Study 35629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity PE (0.3 mA, 90 s)
Number of subjects: 54
Study 35629015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity PE (three pulses of 3 mA, 3 s)
Number of subjects: 54
Study 35629015 — intervention group
Group type: COMPARATOR
Intervention: Sham (without electrical current)
Number of subjects: 54
Study 36317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg daily for 40 days
Number of subjects: 72
Study 36317442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 33113567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (3.75 mg/day)
Number of subjects: 0
Study 33113567 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 0
Study 32203739 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Connections (OC) group intervention
Number of subjects: 33
Study 32203739 — intervention group
Group type: COMPARATOR
Intervention: Open leisure activity group (control condition)
Number of subjects: 33
Study 616649627 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - lock condition
Number of subjects: 101
Study 616649627 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - standard condition
Number of subjects: 101
Study 616649627 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 101
Study 35088720 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study 35088720 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 0
Study 32046865 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PTH levels < 2.9 pmol/L measured 1 hour after surgery and on the first postoperative day
Number of subjects: 143
Study 32046865 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hypocalcemia on the first and fifth postoperative day
Number of subjects: 143
Study 32046865 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of calcium supplements
Number of subjects: 143
Study 32046865 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis of PTH levels
Number of subjects: 143
Study 36235798 — intervention group
Group type: EXPERIMENTAL
Intervention: Two gold kiwifruit (2/day)
Number of subjects: 56
Study 36235798 — intervention group
Group type: COMPARATOR
Intervention: Psyllium (fiber‐matched, 7.5 g/day)
Number of subjects: 56
Study 32588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation plots of ionic ratio (Na+/Cl‐) versus ionic concentration (Cl‐)
Number of subjects: 0
Study 32588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization process for detecting spurious correlation
Number of subjects: 0
Study 32588160 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative tools for detecting induced correlation
Number of subjects: 0
Study 32736141 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % citric acid (CA10) for 90 seconds
Number of subjects: 32
Study 32736141 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 % citric acid (CA50) for 90 seconds
Number of subjects: 32
Study 32736141 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 % citric acid (CA50) for 180 seconds
Number of subjects: 32
Study 32736141 — intervention group
Group type: COMPARATOR
Intervention: Control (C) rinsing with saline solution for 90 seconds
Number of subjects: 32
Study 36062819 — intervention group
Group type: EXPERIMENTAL
Intervention: Early computed tomography coronary angiography
Number of subjects: 1748
Study 36062819 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1748
Study 34580096 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin (2 g three times a day)
Number of subjects: 334
Study 34580096 — intervention group
Group type: COMPARATOR
Intervention: Carbapenem (meropenem 1 g three times a day or ertapenem 1 g once daily)
Number of subjects: 334
Study 34325676 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered physical activity program (FlexToBa™; n = 22)
Number of subjects: 46
Study 34325676 — intervention group
Group type: COMPARATOR
Intervention: Attentional control condition (n = 24)
Number of subjects: 46
Study 32747013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus sorafenib (bevacizumab 5 mg/kg IV every 2 weeks, sorafenib 200 mg bid 5 days-on/2 days-off)
Number of subjects: 54
Study 32747013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus sorafenib
Number of subjects: 54
Study 34655547 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol eye drops administered twice daily
Number of subjects: 201
Study 34655547 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 201
Study 34655547 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 201
Study 32210440 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐?RI/ALK5 inhibitor galunisertib
Number of subjects: 149
Study 32210440 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP responders (21% of patients in Part A with decrease of >20% from baseline)
Number of subjects: 149
Study 32210440 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐?1 responders (51% of all patients)
Number of subjects: 149
Study 33219421 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 11
Study 33219421 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 11
Study 33219421 — intervention group
Group type: COMPARATOR
Intervention: Active rTMS and Sham group
Number of subjects: 11
Study 32653029 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE intervention (Community Reinforcement and Family Training adapted for support persons) consisting of 10 rolling group sessions led by two facilitators.
Number of subjects: 0
Study 32653029 — intervention group
Group type: COMPARATOR
Intervention: Usual care for patients on buprenorphine/naloxone.
Number of subjects: 0
Study 36059921 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 12.5 mg and dexamethasone 8 mg
Number of subjects: 70
Study 36059921 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 70
Study 32941872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy for 23 months after 1 month of ticagrelor combined with aspirin
Number of subjects: 0
Study 32941872 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) for 12 months
Number of subjects: 0
Study 35790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation (2 mA for 20 minutes)
Number of subjects: 16
Study 35790041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS stimulation (2 mA for 20 minutes)
Number of subjects: 16
Study 35790041 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation (control)
Number of subjects: 16
Study 34647197 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength (CAPS) program
Number of subjects: 136
Study 32584909 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) model for predicting obstructive CAD
Number of subjects: 1028
Study 32584909 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) model for revascularization
Number of subjects: 1028
Study 32584909 — intervention group
Group type: COMPARATOR
Intervention: Invasive Coronary Angiography (ICA)
Number of subjects: 1028
Study 32584909 — intervention group
Group type: COMPARATOR
Intervention: Coronary Computed Tomographic Angiography (CCTA)
Number of subjects: 1028
Study 32584909 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of imaging variables from ML model
Number of subjects: 1028
Study 32930638 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week active program based on myofascial release and neurodynamics
Number of subjects: 40
Study 34225686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole in addition to mood stabilisers
Number of subjects: 290
Study 34225686 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to mood stabilisers
Number of subjects: 290
Study 35513882 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) with usual care
Number of subjects: 82
Study 35513882 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 82
Study 32193861 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching real-time videos of colonoscopies (Group A)
Number of subjects: 0
Study 32193861 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching real-time videos of colonoscopies with detailed interpretations (Group B)
Number of subjects: 0
Study 32193861 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 0